stannsoporfin (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

AdultPediatric

See Pediatric Dosing

Hyperbilirubinemia

Pending FDA approval to reduce bilirubin production in neonates at risk for severe neonatal jaundice

Next:

Pharmacology

Mechanism of Action

Heme oxygenase inhibitor; blocks the conversion of heme into bilirubin

Heme is converted to biliverdin by heme oxygenase, and then biliverdin is converted to bilirubin by biliverdin reductase

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.